About Arvinas, Inc.
https://www.arvinas.comArvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
CEO
John G. Houston
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 122
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 20
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:8.56M
Value:$104.45M
BLACKROCK, INC.
Shares:6.8M
Value:$83M
BLACKROCK INC.
Shares:6.26M
Value:$76.36M
Summary
Showing Top 3 of 249
About Arvinas, Inc.
https://www.arvinas.comArvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $41.9M ▲ | $85.7M ▼ | $-35.1M ▲ | -83.77% ▲ | $-0.48 ▲ | $-34M ▲ |
| Q2-2025 | $22.4M ▼ | $93.9M ▼ | $-61.2M ▼ | -273.21% ▼ | $-0.84 ▼ | $-70.1M ▼ |
| Q1-2025 | $188.8M ▲ | $117.4M | $82.9M ▲ | 43.91% ▲ | $1.14 ▲ | $72.7M ▲ |
| Q4-2024 | $59.2M ▼ | $117.4M ▼ | $-45.1M ▲ | -76.18% ▼ | $-0.63 ▲ | $-56.6M ▲ |
| Q3-2024 | $102.4M | $162.7M | $-49.2M | -48.05% | $-0.68 | $-59.2M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $787.6M ▼ | $844.3M ▼ | $279.9M ▼ | $564.4M ▼ |
| Q2-2025 | $861.2M ▼ | $909.3M ▼ | $300M ▼ | $609.3M ▼ |
| Q1-2025 | $954.3M ▼ | $1B ▼ | $341M ▼ | $660.1M ▲ |
| Q4-2024 | $1.04B ▼ | $1.09B ▼ | $529.7M ▼ | $561.7M ▼ |
| Q3-2024 | $1.12B | $1.17B | $581.1M | $586M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-35.1M ▲ | $-59.1M ▲ | $63.5M ▼ | $-17.8M ▼ | $-13.4M ▼ | $-59.2M ▲ |
| Q2-2025 | $-61.2M ▼ | $-95.4M ▼ | $128.8M ▲ | $500K ▲ | $33.9M ▲ | $-96.6M ▼ |
| Q1-2025 | $82.9M ▲ | $-88.9M ▼ | $69.5M ▼ | $-100K ▼ | $-19.5M ▼ | $-89.3M ▼ |
| Q4-2024 | $-45.1M ▲ | $-84.1M ▲ | $98.9M ▲ | $500K ▼ | $15.3M ▲ | $-84.4M ▲ |
| Q3-2024 | $-49.2M | $-128M | $50.5M | $2.4M | $-75.1M | $-128.7M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 License | $0 ▲ | $130.00M ▲ | $130.00M ▲ | $130.00M ▲ |
CEO
John G. Houston
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 122
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 20
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:8.56M
Value:$104.45M
BLACKROCK, INC.
Shares:6.8M
Value:$83M
BLACKROCK INC.
Shares:6.26M
Value:$76.36M
Summary
Showing Top 3 of 249